Sagent Makes ‘Aggressive’ Moves In A ‘Challenging’ US Injectables Market
CEO Vishy Chebrol Talks To Generics Bulletin About Strategy Since Nichi Iko Divestment
Executive Summary
With Sagent Pharmaceuticals operating in an increasingly competitive US injectables market, the company has recently been making moves to bolster its position in the wake of its separation last year from its former parent company, Japan’s Nichi Iko. Chief executive Vishy Chebrol talks to Generics Bulletin about the firm’s strategic goals.